Nizal S. Chandrakumar

Array ( [id] => 17314378 [patent_doc_number] => 20210403426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/458167 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109441 [patent_doc_number] => 20230002321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH [patent_app_type] => utility [patent_app_number] => 17/403742 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718963 [patent_doc_number] => 20220211682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/401522 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17401522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17680014 [patent_doc_number] => 11364245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Use of reboxetine to treat narcolepsy [patent_app_type] => utility [patent_app_number] => 17/398368 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 34687 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656138 [patent_doc_number] => 20230302017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => INOTODIOL AS AGONIST OF LIVER X RECEPTORS, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/019598 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18286573 [patent_doc_number] => 20230102045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => CHEMICALS AND USE OF HYPOHALITES IN MECHANISM-BASED SELECTIVE DUAL RADICAL ORGANIC SYNTHESES [patent_app_type] => utility [patent_app_number] => 17/394680 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17241916 [patent_doc_number] => 20210361659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA [patent_app_type] => utility [patent_app_number] => 17/393553 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356669 [patent_doc_number] => 20220017465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/387648 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368098 [patent_doc_number] => 11648245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators [patent_app_type] => utility [patent_app_number] => 17/387881 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 47740 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 402 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649272 [patent_doc_number] => 20230295058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED COMPOUNDS USING PARAHYDROGEN [patent_app_type] => utility [patent_app_number] => 18/006497 [patent_app_country] => US [patent_app_date] => 2021-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093074 [patent_doc_number] => 20220411415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM [patent_app_type] => utility [patent_app_number] => 17/378410 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 311 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378410 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569881 [patent_doc_number] => 11318135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => Use of Favipiravir in treatment of coronavirus infection [patent_app_type] => utility [patent_app_number] => 17/378361 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 5338 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887633 [patent_doc_number] => 11866394 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Prodrugs of hydroxamate-based GCPII inhibitors [patent_app_type] => utility [patent_app_number] => 17/372899 [patent_app_country] => US [patent_app_date] => 2021-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 31 [patent_no_of_words] => 35400 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17372899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938108 [patent_doc_number] => 20240033247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => USE OF COMPOSITION IN TREATMENT OF CEREBRAL STROKE [patent_app_type] => utility [patent_app_number] => 18/011646 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701447 [patent_doc_number] => 11787946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Deuterated fluorophores [patent_app_type] => utility [patent_app_number] => 17/300459 [patent_app_country] => US [patent_app_date] => 2021-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 70 [patent_no_of_words] => 15621 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17300459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368379 [patent_doc_number] => 20220023431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN [patent_app_type] => utility [patent_app_number] => 17/305311 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875455 [patent_doc_number] => 11447456 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-09-20 [patent_title] => Crystalline form of lamotrigine hydrate, method for preparing the same and composition comprising the same [patent_app_type] => utility [patent_app_number] => 17/366295 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13462 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17183767 [patent_doc_number] => 20210330652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF [patent_app_type] => utility [patent_app_number] => 17/366497 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769305 [patent_doc_number] => 20230364063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 18/013616 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027289 [patent_doc_number] => 11926636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => Crystalline forms of lorlatinib maleate [patent_app_type] => utility [patent_app_number] => 17/365270 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11275 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365270 [rel_patent_id] =>[rel_patent_doc_number] =>)